Jeffrey M. Korentur, Teewinot's chief executive officer stated, "We are proud to add to the technological foundation that will allow this new class of medicines reach their full potential. Our processes, equipment, and expertise will, for the first time, allow for the inexpensive and rapid production of pure cannabinoids and cannabinoid-related compounds for the benefit of patient populations around the world."
With federally licensed laboratories in Canada, an Irish subsidiary, and global headquarters in Tampa, Florida, Teewinot is ready to manufacturer cannabinoids, cannabinoid prodrugs, and cannabinoid analogs worldwide.
About Teewinot Life Sciences Corporation
Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on the use of synthetic biology and advanced formulation for the production and implementation of cannabinoid based therapies. With headquarters in Tampa, Florida, and wholly owned subsidiaries in Canada and Ireland, Teewinot manufactures and licenses technology to make cost effective, pharmaceutically pure, authentic cannabinoids, prodrugs, and analogs as an industry leader in support of advancing medical research and product development. Teewinot's global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid based medicines. For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).
For More Information:
Teewinot Life Sciences Corporation
Heather Pavliga, Teewinot Media Relations
Phone: 888.275.6202, Ext. 738
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/teewinot-life-sciences-secures-first-us-patent-covering-an-apparatus-for-the-biosynthetic-production-of-authentic-thca-cbda-and-cbca-cannabinoids-300300232.html
SOURCE Teewinot Life Sciences Corporation